Call for COVID-19 men to donate plasma

The NHS Blood and Transplant Service is calling for men who have recovered from COVID-19 infection to donate plasma for use in clinical trials.
Men are needed because their plasma is particularly rich in antibodies. Of donations received so far from men, 43% had high enough …

More details...

Prostate cancer most commonly diagnosed cancer 

Prostate cancer has become the UK’s most commonly diagnosed cancer for the first time, according to Prostate Cancer UK (PCUK).
Prostate cancer has overtaken breast, lung and bowel cancer to become the most commonly diagnosed overall with 57 192 diagnoses according to latest annual figures. Prostate cancer diagnoses have more than doubled over the …

More details...

Men’s health absent from policy agendas

Men’s health is generally absent from policies and programmes at all levels, according to a new report from the Global Action on Men’s Health.
From the Margins to the Mainstream takes an in-depth look at the role of policy in men’s health. As well as identifying …

More details...

Caution urged on baldness and COVID-19 claims

There have been media reports that bald men are at higher risk of COVID-19 and should be treated with caution, according to a ‘Fact Check’ by Channel Four News.
The research that led to the claims was conducted in Madrid and published pre-print in the Journal …

More details...

Enzalutamide shows overall survival benefits

Enzalutamide has previously been shown to significantly improve metastasis-free survival in men with nonmetastatic, castration-resistant prostate cancer and rapidly increasing PSA levels while taking androgen-deprivation therapy (ADT). Final results from the PROSPER trial show that overall survival is also increased. 
The final analysis shows that the …

More details...

Oral gonadotrophin antagonist shows promise

A novel oral gonadotropin-releasing hormone (GnRH) antagonist has shown superior testosterone suppression compared to a standard injectable luteinizing hormone–releasing hormone (LHRH).
In the phase 3 trial 622 patients with advanced prostate cancer received the new agent relugolix (120 mg orally once daily) and 308 received leuprolide …

More details...

Don’t omit ADT following radiotherapy

Androgen deprivation therapy (ADT) should be added to external beam radiotherapy (EBRT) in patients with localised prostate cancer and improves overall survival (OS) more than adding a brachytherapy boost (BT), according to a meta-analysis published in the Journal of Clinical Oncology.
Six trials compared EBRT with …

More details...

Surgical versus medical castration in prostate cancer

Surgical castration for metastatic prostate cancer has declined rapidly in recent years but may be an under-utilised option for some men, according to researchers from the USA.
Although medical castration for advanced prostate cancer is the most common form of androgen deprivation, surgical castration represents a …

More details...

Options for hot flush management in prostate cancer

UK Medicines Information (UKMi) has published a review of the current strategies for managing hot flushes associated with hormone treatment for prostate cancer.
Up to 75% of men receiving hormone treatments for prostate cancer have hot flushes. According to the paper sufferers can become drenched in …

More details...

Lookout for non-typical COVID symptoms

Non-typical presentations or manifestations of infection with COVID-19 should not be overlooked and have important implications for a widespread testing programme according to Swiss doctors writing in the BMJ.
Severe acute respiratory illness with fever and respiratory symptoms, such as cough and shortness of breath, are …

More details...

Web design and marketing agency Leamington Spa